1 / 15

Pharmaceuticals Industry

Pharmaceuticals Industry. Cogent and Pharmaceuticals. Pharmaceutical Industry. Pharmaceutical Industry: “Traditional” branch Research = Discovery: new “small” organic molecules (years) Deep competence in drug discovery via Organic Chemistry

maxwell-sanders
Télécharger la présentation

Pharmaceuticals Industry

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmaceuticals Industry Cogent and Pharmaceuticals

  2. Pharmaceutical Industry • Pharmaceutical Industry: “Traditional” branch • Research = Discovery: new “small” organic molecules (years) • Deep competence in drug discovery via Organic Chemistry • Development: pre-clinical & clinical testing and approval (10 years) • Commercialisation (during Patent lifetime; 20 years) • Issues: regulations & approvals; high drug attrition rate; manufacturing costs; national markets e.g., NHS; pipeline value- innovation; international competition incl. Emerging markets • Bio-Pharma: Non-”traditional” branch • Very large biological molecules-bio-pharmaceuticals (nucleic acids, proteins) • Fundamental understanding of human biology and diseases: R&D cutting edge: Big Science • Many SMEs and micros: start-ups, University spin-offs • Cash short; risky: Survival!! • But no escape from long timescale to commercialisation: technical and commercial symbiosis with traditional Pharma

  3. Pharmaceuticals-UK • Largely SE, NW and NE England • £12bn exports; trade balance £3.5bn • 73,000 direct employees (27,000 in R&D); 250,000 related employees • £3.2 bn in UK-based R&D (25% of UK total R&D in manufacturing) • ~100 UK companies producing prescription medicines • UK: 80% all GP prescriptions written generically • Third most profitable UK , after tourism and finance

  4. Sector Skills Councils • Cogent footprint: “SIC Codes” • Manufacture of basic pharmaceutical products (24.41 {03}; 21.10 {08}) • Manufacture of pharmaceutical preparations (24.42; new 21.20) • SEMTA: “Science” (not SIC based) • Research and Development • Bioscience • {There will now be (08) a R&D SIC 72.11 (bio) & 72.19 (Eng & Science)} • Other SSCs: • Skills for Health -pharmacy • Lantra -Animal Technologists • Improve – Food Technologists • SSDA –Pharmaceutical packaging

  5. Cogent going forward • Re-licensing in 2008: • Rationalise the Science-Pharma and Bio-pharma interface • Post Leitch Review of UK Skills: • Cogent the only body to determine vocational Qualifications eligible for funding: Qualifications valued by employers • Sole “owner” of National Occupation Standards (NOS) • Sole owner of Apprenticeship Standards • National Skills Academy for the Processing Industries • Higher Education: • Emerging and critical area for SSCs generally

  6. Current Skills Situation in Pharmaceuticals • Skills Gaps at Levels 2 to 4 • Gaps = employee not fully proficient in current job role • Particular issue with Process and Plant Operatives roles • First line maintenance • Lean manufacture and continuous improvement • Rapid manufacture techniques • Basic chemistry/understanding of processes • Application of knowledge, including graduates’ practical and interpretative skills

  7. Current Skills Situation in Pharmaceuticals • Skills Shortages • Vacancies hard to fill due to lack of suitable candidates • Especially Level 4+, graduates in chemical and molecular biological sciences • The “omics” technologies; synthetic organic chemistry; clinical R&D • University courses declining in relevance • Analytical chemistry • ABPI Report: Sustaining the Skills Pipeline in the Pharmaceutical and Biopharmaceutical Industries; www.abpi.org.uk/Details.asp?ProductID=285

  8. Pharmaceutical Industry-employees Source: LFS 2006

  9. Skills Gaps

  10. Cogent Process Industries – Economic Value of Skills Source: DBERR, Value-Added Scorecard, 2007 • Skills Intensity* Process Industries • High : Medium-High • c.f. Banking : Life Insurance • *measured as average employee cost • Skills and Productivity • Basic skills - employment • Medium skills (FE/HE) - productivity • Higher skills (HE) - sustainability Process Industry - in transition: • Value Added • Speciality Products • Process/Product Innovation • R&D

  11. Demographics, Skills, Education and Training • Leitch (2006/2007) • UK target as world leader in skills • SSCs as regulators of vocational FE • Close collaboration between SSCs and HE Education Headlines • 70% of 2020 workforce already >16 yrs of age • 12% decline in 18 yr olds 2010- 2020 • 40% jobs will require graduate skills by 2020 • 90% of 2+ A’L student in HE (50% Voc Quals) • UK 11 out 30 (OECD) attainment at Level 4 • FE to have FD-awarding status • all 16-18 yr olds to be in educ OR training?

  12. Pharma’s Response • Response part of overall business requirements/pressures • Costs; international competition; M&A; licensing, regulatory, etc • Large organisations becoming leaner, flatter • Less middle-management, more empowered, higher-skilled operational and technical workforce needed • Majors have tradition of in-house training • Small and micro companies: rely on Higher Education; other methods poorly utilised • Other options are to recruit from immigrant population or move manufacturing and/or R&D abroad

  13. Industry Response, c’t’d • Pharma companies and their Trade Associations are engaging with the public skills infrastructure-however it’s cluttered and complicated! • Schools, Colleges- out-reach and influencing teaching and content • HE: notoriously tough to change their cultures • Regional and national entities: RDAs, Business support networks, Government agencies such as Learning and Skills Councils • Self-organised networks are addressing, inter alia skills • E.g., ABPI nationally; NEPIC in NE; Biopharma and Health Technologies Employer Consortium in SE • Networks are of variable strength regionally; many quite lean • Networks want joined-up offering from all providers and agencies

  14. Cogent’s role • In-depth projects, based on deep knowledge of vocational (and soon higher education) provision and mechanisms, to understand and develop solutions for Pharmaceutical and Bio-pharma employers, employees and education and training providers • including close collaboration with SEMTA and fdf • The existing workforce: demographics are: 75% of today’s workforce will still be employed in 2010 • Cogent Gold Standard for up-skilling the existing pharmaceutical workforce • Entering workforce: • Apprenticeship framework (Level 3) • Career pathways: attraction of talent from school age onwards • Higher Education: Level 4+ • Foundation degrees, articulated to Honours Degrees • New Cogent team for Higher Education in 2008

  15. Cogent’s role- c’t’d • Vocational Qualifications: understanding employer needs and translating into qualifications that employers value • Relevant: practical skills combined with underpinning knowledge • Progressive: life-long learning and upskilling • Flexible (modular) provision at work and in classroom • Secure funding from Government for Cogent-approved qualifications • Articulation to honours degree via Foundation Degrees • National Skills Academy for Process Industries • Quality assure provision of all training products and qualifications • Meet individual employers’ individual needs • Shared Skills Needs Database with Cogent for continuing relevance of all training and education of pharmaceutical employees • Skills Brokerage Service: First point of call for any employer • Train to Gain; BIT; but not only these- skills diagnosis and sign-posting to all provision

More Related